Skip to main content

Table 4 Significantly different values in NK cell subsets in controls (Ctrl) and recurrent SCCHN patients

From: Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

% Ctrl t0 t1 t2 t5
CD56bright/CD16
NK cells
1.83 ± 1.14 0.92 ± 0.7* 0.75 ± 0.63* 2.07 ± 1.52 1.6 ± 1.52
CD56bright/CD16+
NK cells
2.52 ± 1.34 2.88 ± 1.85 1.47 ± 0.7* 5.76 ± 4.85 1.54 ± 1.32
CD56dim/CD16
NK cells
2.8 ± 1.8 10.19 ± 11.85 6.08 ± 5.3 4.3 ± 3.97 2.25 ± 2.05
CD56dim/CD16+
NK cells
87.27 ± 5.97 81.4 ± 13.9 88.23 ± 7.52 84.78 ± 11.56 92.88 ± 4.26*
CD56/CD16+
NK cells
0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
  1. The significance is between the two underlined values. E.g. significance in CD56bright/CD16- NK cells between t0 and t1 is *p<=0.05
  2. Composition of NK cell subsets (CD56/CD16) in % (mean value ± standard deviation) in healthy controls (Ctrl, n = 22) and recurrent patients (n = 9) before (t0), after application of 20–30 Gy (t1), 3 months (t2) after RCT and at time of locoregional recurrence (t5, 3–15 months after t0). Significantly different values (Ctrl vs. t0, t1; t0 vs. t1; Ctrl vs. t5) are indicated in bold with an asterisk (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)